On May 17, marks the tenth edition of the World Day Against Hypertension, established to raise awareness of a disease defined by the World Health Organization a “silent and invisible killer”, the first cause of mortality of 9 4 million people in the world.
This year the theme of World Hypertension Day is “Know your blood pressure,” and for this occasion, Daiichi Sankyo Europe in collaboration with the charity Little Hearts organization, launched the initiative “Make Your Heart Feel Good!” to raise funds for orphans sensitize the population about the importance of regular monitoring of blood pressure, in order to prevent the risk of serious cardiovascular and cerebrovascular diseases such as stroke, heart attack and atrial fibrillation.
With this initiative, more than 2,000 employees in 12 subsidiaries in Europe, supports the financing of the project “My family, my hope,” created by Little Hearts in collaboration with the International Association for SOS Children’s Villages help orphans in Europe to live in socio-sanitary conditions in their country of origin.
The project, to be completed by the beginning of next school year is divided into three phases: the selection of teachers based on profiles and experience, preparing them for their new role as “mother” through a series of seminars organized by SOS Children’s Villages, and finally the transformation of the four existing dormitories in four cozy family homes.
High blood pressure is the leading cause of stroke and in a case of stroke one of five, the patient is also suffering from atrial fibrillation. Clinical studies of large populations of patients show that lowering arterial blood pressure significantly reduces the risk of heart attack, stroke and kidney damage.
More and more evidence show that the simplification of therapy increases adherence of hypertensive patients. Therefore, it is preferable to administer a single pill that contains a combination of two drugs at fixed doses. For this reason, Daiichi Sankyo, a leading pharmaceutical company in the cardiovascular area, has developed an association with fixed doses of olmesartan and Norvasc and continues its commitment to research on the benefits of this type of associations to reduce and control blood pressure.
Numerous clinical studies have shown the efficacy of this combination in reducing blood pressure, allowing most patients to achieve their BP targets with a simplified treatment consists of a single pill once daily.
About anti-hypertensive drug Norvasc – Norvasc